318 related articles for article (PubMed ID: 15556875)
1. [Molecular mechanisms involved in hormone resistance of prostate cancer].
Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
[TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
3. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling in androgen-refractory prostate cancer.
Grossmann ME; Huang H; Tindall DJ
J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
[TBL] [Abstract][Full Text] [Related]
5. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
6. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
7. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
9. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
11. Alterations of androgen receptor in prostate cancer.
Linja MJ; Visakorpi T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
[TBL] [Abstract][Full Text] [Related]
12. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer.
Hyytinen ER; Haapala K; Thompson J; Lappalainen I; Roiha M; Rantala I; Helin HJ; Jänne OA; Vihinen M; Palvimo JJ; Koivisto PA
Lab Invest; 2002 Nov; 82(11):1591-8. PubMed ID: 12429819
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
14. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
15. Androgen action and metabolism in prostate cancer.
Green SM; Mostaghel EA; Nelson PS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
18. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
19. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
20. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
